{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:58:21Z","timestamp":1754161101875,"version":"3.41.2"},"reference-count":37,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443293269"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.podrm.2023.11.005","type":"book-chapter","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:18:45Z","timestamp":1706185125000},"page":"81-114","source":"Crossref","is-referenced-by-count":1,"title":["Ponatinib: A comprehensive drug profile"],"prefix":"10.1016","member":"78","reference":[{"year":"2013","series-title":"Nomenclature of\u00a0Organic Chemistry: IUPAC Recommendations and Preferred Names","author":"Favre","key":"10.1016\/bs.podrm.2023.11.005_bib1"},{"key":"10.1016\/bs.podrm.2023.11.005_bib2","series-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","first-page":"1924","author":"Gilman","year":"2001"},{"key":"10.1016\/bs.podrm.2023.11.005_bib3","unstructured":"The name THE MERCK INDEX is owned by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., and is licensed to The Royal Society of Chemistry for use in the U.S.A. and Canada. [cited 2023 9\/4]; from \u3008https:\/\/www.rsc.org\/Merck-Index\/searchresults?searchterm=ponatinib\u3009."},{"issue":"2","key":"10.1016\/bs.podrm.2023.11.005_bib4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/CRST.CRST_98_19","article-title":"Ponatinib: a drug review","volume":"2","author":"Jain","year":"2019","journal-title":"Cancer Res. Stat.\u00a0Treat."},{"key":"10.1016\/bs.podrm.2023.11.005_bib5","unstructured":"CLUSIG\u00ae (ponatinib) tablets for oral use. [prescribing information]CambridgeARIAD Pharmaceuticals, Inc., 2023. Highlights of prescribing information; from \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203469lbl.pdf\u3009."},{"key":"10.1016\/bs.podrm.2023.11.005_bib6","unstructured":"P-7022 Ponatinib, Free Base,>99%. LC Laboratories 2023 [cited 2023 10\/4]; from \u3008https:\/\/www.lclabs.com\/products\/p-7022-ponatinib-free-base\u3009."},{"key":"10.1016\/bs.podrm.2023.11.005_bib7","unstructured":"ponatinib (iclusig) Clinical Drug Experience Knowledgebase 2023 [cited 2023 30\/3]; from \u3008https:\/\/www.cdek.liu.edu\/api\/61947\/\u3009."},{"issue":"9","key":"10.1016\/bs.podrm.2023.11.005_bib8","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1080\/07391102.2019.1640132","article-title":"Ligand-based pharmacophore mapping and virtual screening for identification of potential discoidin domain receptor 1 inhibitors","volume":"38","author":"Vanajothi","year":"2020","journal-title":"J.\u00a0Biomol. Struct.\u00a0Dynam."},{"issue":"1","key":"10.1016\/bs.podrm.2023.11.005_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol.\u00a0Drug Des."},{"key":"#cr-split#-10.1016\/bs.podrm.2023.11.005_bib10.1","unstructured":"L.Zhang, Q. Chen, C. Wu, D. Chang, C. Ha, Bromination Synthesis of 6-Amino-5-Bromoquinoxaline. Jingxi Huagong, 2009. 26(Copyright"},{"key":"#cr-split#-10.1016\/bs.podrm.2023.11.005_bib10.2","unstructured":"(C) 2021 American Chemical Society (ACS). All Rights Reserved.): pp. 575-579."},{"key":"10.1016\/bs.podrm.2023.11.005_bib11","unstructured":"lclusig (ponatinib). European Medicines Agency Science, Medicines Health 2013 [cited 2013 4\/10]; 1\u2013100]. Available from \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/iclusig-epar-public-assessment-report_en.pdf\u3009."},{"issue":"12","key":"10.1016\/bs.podrm.2023.11.005_bib12","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.podrm.2023.11.005_bib13","first-page":"1","author":"Dink","year":"2015","journal-title":"The Synthetic Method of Ponatinib"},{"key":"10.1016\/bs.podrm.2023.11.005_bib14","first-page":"1","author":"Xuenong","year":"2013","journal-title":"Preparation Method for Ponatinib"},{"key":"10.1016\/bs.podrm.2023.11.005_bib15","unstructured":"Ponatinib. StandardPharm Unified standard for Human Health 2023 [cited 2023 4\/10]; from \u3008https:\/\/standardpharm.com\/portal\/list\/index\/catid\/681\/id\/9.html\u3009."},{"issue":"4","key":"10.1016\/bs.podrm.2023.11.005_bib16","doi-asserted-by":"crossref","DOI":"10.1149\/1945-7111\/ac67f6","article-title":"First electrochemical approach to voltammetric behavior and sensing of anticancer drug ponatinib","volume":"169","author":"Koszelska","year":"2022","journal-title":"J.\u00a0Electrochem. Soc."},{"key":"10.1016\/bs.podrm.2023.11.005_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/210503","article-title":"Micellar enhanced spectrofluorimetric method for the determination of ponatinib in human plasma and urine via cremophor RH 40 as sensing agent","volume":"2015","author":"Darwish","year":"2015","journal-title":"Int. J. Anal. Chem."},{"key":"10.1016\/bs.podrm.2023.11.005_bib18","article-title":"Synchronized spectrofluorimetric determination of ponatinib and curcumin as an effective therapeutic combination in laboratory prepared mixtures and human plasma samples","volume":"264","author":"El Sharkasy","year":"2022","journal-title":"Spectrochim. Acta A\u00a0Mol.\u00a0Biomol. Spectrosc."},{"issue":"5","key":"10.1016\/bs.podrm.2023.11.005_bib19","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1021\/acs.jmedchem.9b01546","article-title":"Utilizing stimulated Raman scattering microscopy to study intracellular distribution of label-free ponatinib in live cells","volume":"63","author":"Sepp","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"issue":"2","key":"10.1016\/bs.podrm.2023.11.005_bib20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1248\/bpb.b17-00806","article-title":"Simple determination of plasma ponatinib concentration using HPLC","volume":"41","author":"Yasu","year":"2018","journal-title":"Biol.\u00a0Pharmaceut. Bullet."},{"key":"10.1016\/bs.podrm.2023.11.005_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.leukres.2017.11.012","article-title":"Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients","volume":"64","author":"Abumiya","year":"2018","journal-title":"Leukemia Res."},{"key":"10.1016\/bs.podrm.2023.11.005_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cca.2018.06.035","article-title":"LC-ESI-MS\/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites","volume":"485","author":"Attwa","year":"2018","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/bs.podrm.2023.11.005_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/FTD.0000000000000922","article-title":"Development of a sensitive and high-throughput assay for simultaneous quantification of 5 tyrosine kinase inhibitors and 2 active metabolites in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry","volume":"44","author":"Sumimoto","year":"2022","journal-title":"Therap. Drug Monit."},{"key":"10.1016\/bs.podrm.2023.11.005_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40487-016-0022-2","article-title":"Liquid chromatography\u2013mass spectrometry\/mass spectrometry analysis and pharmacokinetic assessment of ponatinib in sprague\u2013dawley rats","volume":"4","author":"Wang","year":"2016","journal-title":"Oncol.\u00a0Ther."},{"issue":"1","key":"10.1016\/bs.podrm.2023.11.005_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FTD.0000000000000357","article-title":"Development and validation of a simultaneous quantification method of 14 tyrosine kinase inhibitors in human plasma using LC-MS\/MS","volume":"39","author":"Huynh","year":"2017","journal-title":"Therap. Drug Monit."},{"key":"10.1016\/bs.podrm.2023.11.005_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchromb.2016.04.049","article-title":"Liquid chromatography\u2013tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma","volume":"1023","author":"Sparidans","year":"2016","journal-title":"J.\u00a0Chromatogr. B"},{"issue":"10","key":"10.1016\/bs.podrm.2023.11.005_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164967","article-title":"Validated LC-MS\/MS method for the quantification of ponatinib in plasma: application to metabolic stability","volume":"11","author":"Kadi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.podrm.2023.11.005_bib28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2017.11.060","article-title":"High throughput routine determination of 17 tyrosine kinase inhibitors by LC\u2013MS\/MS","volume":"150","author":"Merienne","year":"2018","journal-title":"J.\u00a0Pharmaceut.\u00a0Biomed. Anal."},{"issue":"8","key":"10.1016\/bs.podrm.2023.11.005_bib29","article-title":"Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high\u2010performance liquid chromatography\u2013Photodiode array detection","volume":"36","author":"Yokoyama","year":"2022","journal-title":"J.\u00a0Clin. Lab. Anal."},{"key":"10.1016\/bs.podrm.2023.11.005_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ab.2019.02.010","article-title":"Development of a sandwich enzyme-linked immunosorbent assay for the quantification of ponatinib in serum","volume":"571","author":"Yamamoto","year":"2019","journal-title":"Anal. Biochem."},{"issue":"5","key":"10.1016\/bs.podrm.2023.11.005_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/bs.podrm.2023.11.005_bib32","first-page":"507","article-title":"Absorption, metabolism, and excretion of [14C] ponatinib after a single oral dose in humans","volume":"79","author":"Yihua","year":"2017","journal-title":"Cancer Chemother.\u00a0Pharmacol."},{"issue":"6","key":"10.1016\/bs.podrm.2023.11.005_bib33","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/ijc.32924","article-title":"Lipid droplet\u2010mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib","volume":"147","author":"Englinger","year":"2020","journal-title":"Int.\u00a0J.\u00a0Cancer"},{"key":"10.1016\/bs.podrm.2023.11.005_bib34","unstructured":"Cortez, J. Ponatinib starting dose may be linked to efficacy, safety in chronic-phase CML. Healio September 15, 2020 [cited 2023 4\/10]; from \u3008https:\/\/www.healio.com\/news\/hematology-oncology\/20200915\/ponatinib-starting-dose-may-be-linked-to-efficacy-safety-in-chronicphase-cml\u3009."},{"issue":"6","key":"10.1016\/bs.podrm.2023.11.005_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4819","article-title":"In vitro metabolites characterization of ponatinib in human liver microsomes using ultra\u2010high performance liquid chromatography combined with Q\u2010Exactive\u2010Orbitrap tandem mass spectrometry","volume":"34","author":"Gao","year":"2020","journal-title":"Biomed. Chromatogr."},{"issue":"76","key":"10.1016\/bs.podrm.2023.11.005_bib36","doi-asserted-by":"crossref","first-page":"72575","DOI":"10.1039\/C6RA09985H","article-title":"Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways","volume":"6","author":"Kadi","year":"2016","journal-title":"RSC Adv."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512523000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512523000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:15:33Z","timestamp":1753715733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512523000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443293269"],"references-count":37,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2023.11.005","relation":{},"ISSN":["1871-5125"],"issn-type":[{"type":"print","value":"1871-5125"}],"subject":[],"published":{"date-parts":[[2024]]}}}